Teva concludes patient enrollment in multiple sclerosis drug Phase III trial
Patient enrollment was completed in May 2011, recruiting over 1,400 patients at 180 sites in the US, Europe, Central Eastern Europe and Israel. The primary endpoint of the
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).